ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ

Тестирование моноклональных антител к Т-клеточному рецептору, ассоциированному с анкилозирующим спондилитом

М. А. Израельсон1,3, А. В. Степанов2, Д. Б. Староверов1,3, И. А. Шагина1, А. К. Мисорин4, А. В. Евстратьева4, Е. М. Мерзляк1,3, Е. А. Богданова1, О. В. Британова3, С. А. Лукьянов1
Информация об авторах

1 Отдел молекулярных технологий, Институт трансляционной медицины,
Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва

2 Отдел пептидно-белковых технологий, Институт биоорганической химии имени М. М. Шемякина и Ю. А. Овчинникова, Москва

3 Отдел геномики адаптивного иммунитета, Институт биоорганической химии имени М. М. Шемякина и Ю. А. Овчинникова, Москва

4 BIOCAD, Санкт-Петербург

Для корреспонденции: Ольга Владимировна Британова
ул. Миклухо-Маклая, д. 16/10, г. Москва, 117997; moc.liamg@natirblo

Информация о статье

Финансирование: работа выполнена при поддержке Минобрнауки России, идентификатор соглашения RFMEFI60716X0158.

Статья получена: 13.09.2018 Статья принята к печати: 11.10.2018 Опубликовано online: 04.12.2018
|
  1. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled shortterm trial. Ann Rheum Dis. 2014; 73 (1): 243–6.
  2. Rihl M, Baerlecken N, Wiese B, Schmidt RE, Zeidler H. Intravenous glucocorticoid pulse therapy in active, NSAID refractory axial ankylosing spondylitis: a retrospective analysis spanning 12 months. J Arthritis. 2018; (7): 1. DOI: 10.4172/2167- 7921.1000266
  3. Fujita T, Kutsumi H, Sanuki T, Hayakumo T, Azuma T. Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries. J. Gastroenterol. 2013; (48): 559–73. DOI: 10.1007/s00535-013- 0771-8
  4. Xu T, Ying T, Wang L, Zhang XD, Wang Y, Kang L et al. A nativelike bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factoralpha and interleukin-17A. Oncotarget. 2017; 8 (47): 81860–72. DOI: 10.18632/oncotarget.19899.
  5. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; (70): 905–8.
  6. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al.Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359 (9313): 1187–93.
  7. Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA et al. A randomized, double-blind, placebocontrolled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. (Hoboken, N.j). 2015; 67 (10): 2702–12. DOI: 10.1002/art.39257.
  8. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee MJ, Rahbar MH, et al. The impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis Rheumat. 2013; 65 (10): 2645–54. DOI: 10.1002/art.38070.
  9. Callhoff J, Sieper J, Weiss A, Zink A, Listing J. Efficacy of TNF blockers in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis: a meta-analysis. Ann. Rheum. Dis. 2015; (74): 1241–48.
  10. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P et al Antiinterleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebocontrolled trial. Lancet. 2013; 382 (9906): 1705–13.
  11. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P. et al/ Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015; (373): 2534–48.
  12. Helling B, König M, Dälken B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015; 93 (4): 396–405. DOI: 10.1038/icb.2014.102
  13. Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016; 8 (8): 889–906.
  14. König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J. Tregalizumab – A Monoclonal antibody to target regulatory T cells. Front Immunol. 2016; (7): 11. DOI: 10.3389/fimmu.2016.00011
  15. Duarte J, Agua-Doce A, Oliveira V, Fonseca JE, Graca L. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS One. 2010; 5 (5): e10558. DOI: 10.1371/journal.pone.0010558
  16. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3- specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med. 2008: 14 (5): 528–35. DOI: 10.1038/nm1749.
  17. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol. 2006; (6): 883–94.
  18. Lavasani S, Dzhambazov B, Andersson M. Monoclonal antibody against T-cell receptor αβ induces self-tolerance in chronic experimental autoimmune encephalomyelitis. Scandinavian Journal of Immunology. 2007; (65): 39–47. DOI: 10.1111/j.1365- 3083.2006.01866.x
  19. Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee Ji-Y, Olshen RA, Weyand C, Boyd SD, and Goronzy JJ. Diversity and clonal selection in the human T-cell repertoire. PNAS. 2014; 111 (36): 13139–44. https://DOI.org/10.1073/pnas.1409155111.
  20. Faham M, Carlton V, Moorhead M, Zheng J, Klinger M, Pepin F. et al. Discovery of T cell receptor β motifs specific to HLA–B27– Positive ankylosing spondylitis by deep Repertoire sequence analysis. Arthritis & Rheumatology. 2017; (69): 774–84. DOI: 10.1002/art.40028
  21. Komech E, Pogorelyy M, Egorov E, Britanova O, Rebrikov D, Bochkova A, et al. CD8+ T cells with characteristic T cell receptor beta motif are detected in blood and expanded in synovial fluid of ankylosing spondylitis patients. Rheumatology. 2018, 579 (6): 1097–104. https://DOI.org/10.1093/rheumatology/kex517
  22. Stewart R, Thom G, Levens M, Güler-Gane G, Holgate R, Rudd PM et al. A variant human IgG1-Fc mediates improved ADCC. Protein Engineering, Design and Selection. 2011; 24 (9): 671–8. https://DOI.org/10.1093/protein/gzr015
  23. Britanova OV, Shugay M, Merzlyak EM, Staroverov DB, Putintseva EV, Turchaninova MA et al. Dynamics of Individual T Cell Repertoires: From Cord Blood to Centenarians. J. Immunol. 2016; 15, 196 (12): 5005–13. DOI: 10.4049/jimmunol.1600005.
  24. Shugay M, Bagaev DV, Turchaninova MA, Bolotin DA, Britanova OV, Putintseva EV. et al. VDJtools: Unifying Postanalysis of T Cell Receptor Repertoires. PLoS computational biology. 2015; (11): e1004503.
  25. Egorov ES, Kasatskaya SA, Zubov VN, Izraelson M, Nakonechnaya TO, Staroverov DB et al. The changing landscape of naive T cell receptor repertoire with human aging. Front Immunol. 2018; (9): 1618. https://DOI.org/10.3389/fimmu.2018.01618
  26. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 1968; 14 (2): 181–96.
  27. Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, et al. A novel method for evaluating antibodydependent cell-mediated cytotoxicity by flow cytometry using cryopreserved human peripheral blood mononuclear cells. Sci Rep. 2016; (6): 19772. DOI: 10.1038/srep19772
  28. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988; 54 (2): 263–73.
  29. Chiocchia G, Boissier M, Fournier, C. Therapy against murine collagen-induced arthritis with T cell receptor Vβ-specific antibodies. Eur J Immunol. 1991; (21): 2899–905. DOI:10.1002/ eji.1830211202
  30. Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009; 5 (5): 499–521.
  31. Bruno V, Battaglia G, Nicoletti F. The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurol Sci. 2011; 31 (Suppl 3): 283–288. DOI 10.1007/s10072- 010-0382-6